AU Patent

AU2017246228B2 — Soluble C5aR antagonists

Assigned to Chemocentryx Inc · Expires 2021-04-15 · 5y expired

What this patent protects

Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R

USPTO Abstract

Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R

Drugs covered by this patent

Patent Metadata

Patent number
AU2017246228B2
Jurisdiction
AU
Classification
—
Expires
2021-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.